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Abstract
Background: Guidelines from the American Heart Association/American College of Cardiology recommend a
higher dosage of aspirin daily following Percutaneous Coronary Intervention (PCI), whereas guidelines from the
European Society of Cardiology recommend a lower dosage. This study aimed to compare the adverse clinical
outcomes associated with a low dose and a high dose of aspirin following PCI.
Methods: Electronic databases were searched for studies comparing a low dose with a high dose aspirin following PCI.
Adverse clinical outcomes were considered as the endpoints in this study. We calculated Odds Ratios (OR) with 95 %
Confidence Intervals (CIs) for categorical variables. The pooled analyses were performed with RevMan 5.3 software.
Results: A total number of 25,083 patients were included. Results from this analysis showed that the combination of
Cardiovascular (CV) death/Myocardial Infarction (MI) or stroke was not significantly different between a low and high
dose of aspirin with OR: 1.08, 95 % CI: 0.98–1.18; P = 0.11. Mortality and MI were also not significantly different between
these two treatment regimens following PCI with OR: 0.95, 95 % CI: 0.74–1.23; P = 0.71 and OR: 1.17, 95 % CI: 0.97–1.41;
P = 0.09 respectively. However, a high dose of aspirin was associated with a significantly higher rate of Major Adverse
Cardiac Events (MACEs) with OR: 1.20, 95 % CI: 1.02–1.41; P = 0.03. Thrombolysis In Myocardial Infarction (TIMI) defined
minor bleeding was also significantly higher with a high dose aspirin with OR: 1.22, 95 % CI: 1.02–1.47; P = 0.03. When
Stent thrombosis (ST) was compared, no significant difference was found with OR: 1.28, 95 % CI: 0.59–2.58; P = 0.53.
Even if TIMI defined major bleeding favored a low dose of aspirin, with OR: 1.42, 95 % CI: 0.95–2.13; P = 0.09, or even if
major bleeding was insignificantly higher with a high dose aspirin, with OR: 1.78, 95 % CI: 1.01–3.13; P = 0.05; I2 = 94 %,
higher levels of heterogeneity observed in these subgroups could not be considered significant to any extent.
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Conclusion: According to the results of this analysis, a high dose of aspirin following PCI was not associated with any
significantly higher rate of CV death/MI/stroke, mortality or MI. However, MACEs significantly favored a low dose of
aspirin. In addition, TIMI defined minor bleeding was significantly higher with a high dose of aspirin whereas the results
for the major bleeding outcomes were not statistically significant. However, due to limited data availability and since
the subgroups analyzing major bleeding were highly heterogeneous, further studies are recommended to completely
solve this issue.
Keywords: Aspirin, Percutaneous coronary intervention, Bleeding, Major adverse cardiac events, Cardiovascular death,
Meta-analysis
Abbreviations: ACS, Acute coronary syndrome; MACEs, Major adverse cardiac events; OR, Odds ratio; PCI, Percutaneous
coronary intervention; TIMI defined bleeding, Thrombolysis in myocardial infarction defined bleeding
Background
Percutaneous Coronary Intervention (PCI) is considered to
be among the most preferred invasive procedures carried
out in patients with Acute Coronary Syndrome (ACS).
Dual Anti-Platelet Therapy (DAPT) with aspirin and a
P2Y12 inhibitor mainly clopidogrel, showed increased ben-
efits in reducing adverse clinical outcomes following PCI
with Drug Eluting Stents (DES) or Bare Metal Stents
(BMS) [1]. Therefore, the American College of Cardiology/
American Heart Association [2] recommends at least one-
year treatment with DAPT after PCI with DES whereas the
European Society of Cardiology [3] recommends 6 to
12 months DAPT use after intracoronary stenting by DES.
For BMS, the duration period for DAPT is even shorter
(1 month) compared to DES. However, uncertainty regard-
ing the optimal dosage of aspirin is still a fact which re-
mains to be solved [4]. Guidelines from the American
Heart Association/American College of Cardiology recom-
mend higher doses of aspirin (162 to 325 mg) daily follow-
ing PCI [5], whereas guidelines from the European Society
of Cardiology recommend lower doses (75 to 100 mg) [6].
This current analysis aimed to compare the adverse clinical
outcomes associated with a low dose and a high dose of as-
pirin in patients with ACS following PCI with either DES
or BMS.
Methods
Data sources and search strategy
The Cochrane Library, PubMed, Medline and EMBASE
were searched for studies comparing a low dose with a high
dose of aspirin following PCI by typing the words or
phrases ‘low and high dose aspirin and percutaneous coron-
ary intervention’. Another search was conducted using the
words ‘aspirin and acute coronary syndrome or drug eluting
stents/bare metal stents’ [aspirin + acute coronary syn-
drome/aspirin + percutaneous coronary intervention/as-
pirin + drug eluting stents/bare metal stents/low and/or
high dose aspirin + percutaneous coronary intervention]. In
order to enhance this search, abbreviations such as ASA,
ACS, DES/BMS and PCI were also used as well as the
terms ‘coronary angioplasty’, ‘coronary intervention’ and ‘sin-
gle or double dose aspirin’ [ASA + PCI/ASA+ percutaneous
coronary intervention/ASA + acute coronary syndrome/
ASA+ACS/ASA +DES/BMS/ASA+ coronary angioplasty].
Medical journals which were expected to publish articles
related to coronary interventions such as the Journal of
Circulation, the Journal of the American College of
Cardiology, Euro-intervention, the American Journal
of Cardiology and BMC cardiovascular disorders were
also searched using the above mentioned terms for
relevant articles. Moreover, reference lists of suitable
articles were also searched for relevant studies. This
search was restricted to articles published in English.
Inclusion and exclusion criteria
Studies were included if:
(a)They were Randomized Controlled Trials (RCTs) or
observational studies comparing a low dose with a
high dose of aspirin following PCI.
(b)They reported adverse outcomes as their clinical
endpoints.
(c)They involved any dosage of aspirin, as far as a low
dose was compared with a high dose.
Studies were excluded if:
(a)They were meta-analyses, letter to editors and case
studies.
(b)They did not report adverse outcomes as their
clinical endpoints.
(c)They were duplicates.
Outcomes, definitions and follow ups
The clinical endpoints analyzed included:
(a)Mortality
(b)Myocardial Infarction (MI)
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(c)Cardiovascular (CV) death/MI/stroke
(d)Major adverse cardiac events (MACEs) consisting of
death, MI and revascularization
(e)Stent Thrombosis (ST)
(f )Major bleeding which was defined as bleeding that
was significantly disabling for example intraocular
bleeding that lead to significant vision loss, or
bleeding requiring transfusion of 2 units of red
blood cells or equivalent whole blood, a drop in
hemoglobin concentration of 5 g/L, bleeding causing
significant hypotension requiring intravenous
inotropes or surgical intervention, symptomatic
intracranial hemorrhage or bleeding that was fatal
(g)TIMI defined major bleeding [7]
(h)TIMI defined minor bleeding
The outcomes reported and the dosage of aspirin re-
ported among the cohorts as well as their corresponding
follow up periods have been summarized in Table 1.
A low dosage of aspirin was defined as any low dosage
in accordance to the high dosage of aspirin reported in
the same study. For example, if a dosage of aspirin greater
than 200 mg was considered a high dosage, then any dos-
age below 200 mg in the same study should be considered
as a low dosage.
Data extraction and quality assessment
Three authors (PKB, GJ and ART) independently assessed
the articles selected for this analysis. Information con-
cerning the type of study reported, the total number of
patients treated with a low and high dose of aspirin re-
spectively, data concerning the baseline characteristics of
the patients, the reported outcomes and follow up periods
were carefully extracted. If any disagreement about includ-
ing certain data occurred, it was discussed among these
three authors and if they could not reach a consensus, a
final decision was made by the fourth author (WQH). Bias
risk was assessed in accordance to the components rec-
ommended by the Cochrane Collaboration [8].
Methodological quality and statistical analysis
Recommendations of the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) state-
ment were followed since this is a meta-analysis involving
mostly trials [9]. Heterogeneity across the subgroups was
assessed using the Cochrane Q-statistic test (whereby a
P value < 0 · 05 was considered statistically significant
whereas a P value > 0.05 was considered statistically insig-
nificant) and the I2-statistic test (whereby an I2 with low
percentage represented a lower heterogeneity and an in-
creasing percentage denoted an increasing heterogeneity).
If I2 was less than 50 %, a fixed effect model was used.
However, if I2 was more than 50 %, a random effect model
was used. Publication bias was visually estimated by asses-
sing funnel plots. We calculated Odds Ratios (OR) and
95 % Confidence Intervals (CIs) for categorical variables.
The pooled analyses were performed with RevMan 5.3
software. Ethical approval was not required for systematic
reviews and meta-analyses. All the authors had full access
to the data and approved the manuscript as written.
Results
Search results
A total number of 622 articles were obtained from the
Cochrane Library, PubMed, Medline and EMBASE and
from reference lists of suitable articles. After a careful
assessment of titles and abstracts, 584 articles were elim-
inated since they were not related to our topic. A further
26 articles were eliminated since they were duplicates.
12 full-text articles were assessed for eligibility. Eight
more articles were eliminated: one article was a system-
atic review of the literature, two article did not report
adverse clinical outcomes and two articles which could
probably satisfy the inclusion and exclusion criteria of
our study were not made available by the authors, one
article did not include data which could be used in this
analysis, and another two trials were the subset of other
trials included in this analysis. Finally, four articles (3 trials
and 1 observational study) [4, 10–13] were included in this
systematic review and meta-analysis. The flow diagram for
the study selection has been represented in Fig. 1.
General features of the studies included
The general features of the studies included in this
meta-analysis have been listed in Table 2.
A total number of 25,083 patients (14,402 patients
were assigned to a low dose of aspirin and 10,681 patients
were assigned to a high dose of aspirin) were included in
this analysis.
Table 1 Reported outcomes
Studies Outcomes reported Dosage of aspirin Follow up periods
GHOST MACEs, ST, Death or MI, TIMI bleeding 81 mg vs 160–325 mg 1 year
CURRENT OASIS 7 Death/MI/stroke, death, MI, stroke, TIMI major and minor bleeding ≤100 mg vs ≥ 300 mg 30 days
CURE CV death/MI/stroke, major bleeding <200 mg vs ≥ 200 mg 1 year
HORIZONS-AMI MACEs, mortality, MI, stroke, major bleeding, TIMI major and minor bleeding, ST ≤200 mg vs > 200 mg 3 years
Abbreviations: MI myocardial infarction, TIMI thrombolysis in myocardial infarction, MACEs major adverse cardiac events, ST stent thrombosis, CV cardiovascular
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Baseline characteristics of the studies included
The baseline features of the patients have been listed in
Table 3 whereas Table 4 shows the other antiplatelet/
anticoagulants used by the patients during the procedure
or following PCI. According to these baseline features, no
significant differences were observed between patients
assigned to a low dose and a high dose of aspirin
respectively.
Clinical outcomes reported
Results from this analysis (Table 5) showed that the com-
bination of CV death/MI or stroke was not significantly
different between a low and a high dose of aspirin fol-
lowing PCI with OR: 1.08, 95 % CI: 0.98–1.18; P = 0.11,
I2 = 0 %. Mortality and MI were also not significantly dif-
ferent between these two treatment regimens after PCI
with OR: 0.95, 95 % CI: 0.74–1.23; P = 0.71, I2 = 7 % and
OR: 1.17, 95 % CI: 0.97–1.41; P = 0.09, I2 = 33 % respect-
ively. However, a high dose of aspirin was associated with
a significantly higher rate of MACEs with OR: 1.20, 95 %
CI: 1.02–1.41; P = 0.03, I2 = 35 %. TIMI defined minor
bleeding was also significantly higher with a high dose
aspirin with OR: 1.22, 95 % CI: 1.02–1.47; P = 0.03;
I2 = 44 %. These results have been represented in Fig. 2.
Fig. 1 Flow diagram representing the study selection
Table 2 General features of the studies included
Studies Type of study No of patients with
low dose ASA (n)
No of patients with
high dose ASA (n)
Total no of patients (n) Type of P2Y12 inhibitor used
GHOST [10] observational 313 2507 2820 clopidogrel
CURRENT OASIS 7 [11] RCT 3371 3502 6873 clopidogrel
CURE [4, 12] RCT 8429 4110 12,539 clopidogrel
HORIZONS-AMI [13] RCT 2289 562 2851 clopidogrel
Total no of patients (n) 14,402 10,681 25,083
Only female patients were included from trial CURRENT OASIS 7 in order to avoid the influence of this trial on the results of this analysis
Abbreviations: ASA aspirin, RCT randomized controlled trials
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When ST was compared between these two groups,
no significant difference was found with OR: 1.28, 95 %
CI: 0.59–2.58; P = 0.53, I2 = 65 %. Even if TIMI defined
major bleeding favored a low dose aspirin, with OR:
1.42, 95 % CI: 0.95–2.13; P = 0.09; I2 = 59 %, the result
was not statistically significant. Moreover, even if major
bleeding was higher with a high dose aspirin, with
OR: 1.78, 95 % CI: 1.01–3.13; P = 0.05; I2 = 94 %, the level
of heterogeneity was much higher that it could not be
considered significant to any extent. These results have
been represented in Fig. 3.
For all of the above analyses, sensitivity analyses
yielded consistent results. Based on a visual inspection
of the funnel plot obtained, there has been little evidence
of publication bias for the included studies that assessed
several clinical endpoints. However, a high level of het-
erogeneity was observed among the subgroups analyzing
stent thrombosis and the major bleeding outcomes. The
funnel plot showing the sensitivity analysis has been rep-
resented in Fig. 4.
Discussion
This study aimed to compare the adverse clinical out-
comes associated with a low dose and a high dose of
aspirin following PCI. Results of this study showed that
a high dose of aspirin was not associated with a signifi-
cantly higher rate of mortality, CV death/MI/stroke and
MI. ST was also not significantly different between these
two dosages of aspirin. However, MACEs significantly
favored a low dose aspirin. In addition, a high dose of as-
pirin was associated with a significantly higher rate of
TIMI defined minor bleeding, without any significant in-
crease in TIMI defined major bleeding major bleeding
after PCI.
The systematic review of literature [14] which was
meant to show any association between aspirin dosing
and cardiac and bleeding events after treatment of ACS
showed no improved clinical outcomes associated with a
high dose of aspirin following PCI among the 289,330
patients analyzed. 2.1 % of patients experienced major
bleeding when treated with a high dose of aspirin
whereas only 1.9 % of patients treated with a low dose of
aspirin following stent implantation experienced major
bleeding.
Moreover, the investigators of the CURRENT OASIS 7
[11] concluded that in patients with ACS who were re-
ferred for an invasive strategy, no significant difference
in primary outcome of cardiovascular death, MI or
stroke was observed between a low and a high dose of
aspirin. However, only a follow up period of 7 days was
considered.
Also, the study published by Joyal et al. [15] demon-
strating the influence of a low dose (81 mg) versus a
high dose (325 mg) of aspirin on the incidence of siroli-
mus eluting stents showed a similar rate of ST to be as-
sociated with either a low or a high dose of aspirin. The
Table 3 Baseline features of the patients included in this analysis
Studies Mean age (years) Males (%) Ht (%) Ds (%) Cs (%) DM (%)
L/H L/H L/H L/H L/H L/H
GHOST 67.0/64.0 64.0/70.0 73.0/65.0 76.0/72.0 19.0/27.0 12.0/8.0
CURRENT OASIS 7 61.2/61.5 0.00/0.00 60.2/60.4 40.9/41.4 33.6/33.2 23.1/23.8
CURE - 58.8/65.4 58.8/60.5 - 20.8/25.1 21.0/26.8
HORIZONS-AMI 59.9/58.8 76.3/79.4 50.6/58.2 42.3/47.9 65.0/63.5 16.6/15.8
Abbreviations: L low dose, H high dose, Ht hypertension, Ds dyslipidemia, Cs current smoker, DM diabetes mellitus
Table 4 Other antiplatelet/anticoagulants used by the patients
included in this analysis
Other antiplatelets/
anticoagulants
GHOST CURRENT OASIS 7 CURE HORIZONS-AMI
Heparin +++ − − −
GP IIb/IIIa inhibitors + + +++ −
Oral anticoagulants
(warfarin/Coumadin)
+ − + +
Clopidogrel ++++ ++++ ++++ ++++
Abbreviations: GP glycoproteins, “+”: less than 25 % of patients, “++”: 26 to
50 % of patients, “+++”: 51 to 75 % of patients, “++++”: 76 to 100 %
of patients
Table 5 Results of this analysis
Outcomes analyzed OR with 95 % CI P value I2 (%)
Mortality 0.95 [0.74–1.23] 0.71 7
MI 1.17 [0.97–1.41] 0.09 33
CV death/MI/stroke 1.08 [0.98–1.18] 0.11 0
MACEs 1.20 [1.02–1.41] 0.03 35
ST 1.28 [0.59–2.78] 0.53 65
Major bleeding 1.78 [1.01–3.13] 0.05 94
TIMI major bleeding 1.42 [0.95–2.13] 0.09 59
TIMI minor bleeding 1.22 [1.02–1.47] 0.03 44
Abbreviations: MI myocardial infarction, TIMI thrombolysis in myocardial
infarction, MACEs major adverse cardiac events, ST stent thrombosis,
CV cardiovascular, OR odds ratio, CI confidence intervals
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Ottawa Heart Institute PCI Registry [16] which involved
930 patients discharged on 325 mg aspirin and 910 pa-
tients discharged on 81 mg aspirin showed no difference
in death or MI at 1 year between these two different
dosages of aspirin. In addition, another study investigat-
ing the influence of low dose aspirin (81 mg) on the inci-
dence of definite stent thrombosis in patients receiving
BMS and DES concluded that a low dose of aspirin fol-
lowing PCI was not associated with any increase in
definite stent thrombosis compared to a high dose [17].
However, results from the Dual Antiplatelet Therapy
Study [18] showed that a high dose of aspirin might be
associated with adverse events and the authors suggested
that a low dose of aspirin might be the target to improve
clinical outcomes after PCI reflecting the results of this
current analysis.
Nevertheless, when prasugrel was compared with clo-
pidogrel, with a high and low dose aspirin respectively,
prasugrel was associated with better clinical outcomes
irrespective of the dosage of aspirin as demonstrated in
the TRITON TIMI 38 trial whereby 12,674 patients were
classified into a low and high dose aspirin groups [19].
No meaningful interaction of aspirin with clopidogrel
was observed. However, this current analysis was differ-
ent and was focused mainly on comparing a low with a
high dose of aspirin following PCI.
Fig. 2 Adverse clinical outcomes reported between a low and a high dose of aspirin
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Novelty
This study is new in the way that it is among the first
systematic review and meta-analyses comparing a low
dose with a high dose of aspirin following PCI. More-
over, several adverse outcomes have been analyzed. This
study also included a large number of patients from ran-
domized trials compared to patients from observational
studies and reported a low or moderate level of hetero-
geneity among several subgroups assessing these clinical
endpoints. Since dosage of aspirin following PCI could
Fig. 3 Stent thrombosis, major bleeding outcomes reported between a low and a high dose of aspirin
Fig. 4 Funnel plot showing sensitivity analysis
Bundhun et al. BMC Cardiovascular Disorders  (2016) 16:169 Page 7 of 9
be an important issue in several types of patients, this
analysis could inspire other scientists to conduct further
research in this particular field.
Limitations
This study also has limitations. First of all, due to the
limited number of patients and studies, this analysis
might not provide robust results. Secondly, because this
analysis also included data obtained from observational
studies along with data obtained from randomized trials,
selection bias could possibly have been introduced.
Moreover, one study had a follow-up period of 3 years
and another one had a follow up period of 1 month.
They have been included among other studies with a
follow-up period of 1 year and analyzed altogether. This
could be another limitation. In addition, several sub-
groups analyzed only compared data from two or three
studies which could strictly affect the results and should
be considered another limiting factor in this meta-
analysis. A high level of heterogeneity observed among
the several subgroups analyzing stent thrombosis, and
major bleedings could be another limitation in this
study. In addition, different studies reported different
dosage of aspirin. This could also be a limiting factor in
this study. Also, only the percentage of patients repre-
senting the female population were included from the
trial CURRENT OASIS 7, because its large number of
patients could influence the results of this analysis.
Therefore, this could also be a limitation in this study. It
should also be noted that patients involved in this ana-
lysis varied from stable coronary diseases, ST segment
elevated MI or non-ST segment elevated MI represent-
ing another probable limitation to this study. However,
the main focus was on patients who underwent PCI.
Also, almost all of the studies were sub-group analysis of
trials whereby patients were not randomized specifically
to a low and high dosage of aspirin respectively,
therefore, the groups might not necessarily be com-
parable thus rendering the introduction of potentially
confounding variables possible, which could have a
great impact on the results of this current analysis.
Another limitation could be the influence of glyco-
protein IIb/IIIa inhibitors used peri-operatively, and
other anticoagulants which were used differently fol-
lowing PCI in different studies, possibly affecting the
bleeding outcomes.
Conclusion
According to the results of this analysis, a high dose of
aspirin following PCI was not associated with any sig-
nificantly higher rate of CV death/MI/stroke, mortality
or MI. However, MACEs significantly favored a low dose
of aspirin. In addition, TIMI defined minor bleeding was
significantly higher with a high dose of aspirin whereas
the results for the major bleeding outcomes were not
statistically significant. However, due to limited data
availability and since the subgroups analyzing major
bleeding were highly heterogeneous, further studies are
recommended to completely solve this issue.
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